- Home
- IHD vs BDTX Comparison
IHD vs BDTX Comparison
Compare IHD & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IHD
- BDTX
- Stock Information
- Founded
- IHD 2011
- BDTX 2014
- Country
- IHD United States
- BDTX United States
- Employees
- IHD N/A
- BDTX N/A
- Industry
- IHD Investment Managers
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IHD Finance
- BDTX Health Care
- Exchange
- IHD Nasdaq
- BDTX Nasdaq
- Market Cap
- IHD 89.7M
- BDTX 96.9M
- IPO Year
- IHD N/A
- BDTX 2020
- Fundamental
- Price
- IHD $5.28
- BDTX $1.58
- Analyst Decision
- IHD
- BDTX Strong Buy
- Analyst Count
- IHD 0
- BDTX 5
- Target Price
- IHD N/A
- BDTX $15.60
- AVG Volume (30 Days)
- IHD 27.7K
- BDTX 8.4M
- Earning Date
- IHD 01-01-0001
- BDTX 05-08-2025
- Dividend Yield
- IHD 10.32%
- BDTX N/A
- EPS Growth
- IHD N/A
- BDTX N/A
- EPS
- IHD N/A
- BDTX N/A
- Revenue
- IHD N/A
- BDTX N/A
- Revenue This Year
- IHD N/A
- BDTX N/A
- Revenue Next Year
- IHD N/A
- BDTX N/A
- P/E Ratio
- IHD N/A
- BDTX N/A
- Revenue Growth
- IHD N/A
- BDTX N/A
- 52 Week Low
- IHD $4.49
- BDTX $1.43
- 52 Week High
- IHD $5.47
- BDTX $7.66
- Technical
- Relative Strength Index (RSI)
- IHD 46.13
- BDTX 39.89
- Support Level
- IHD $5.31
- BDTX $1.55
- Resistance Level
- IHD $5.40
- BDTX $1.84
- Average True Range (ATR)
- IHD 0.06
- BDTX 0.21
- MACD
- IHD -0.01
- BDTX 0.00
- Stochastic Oscillator
- IHD 10.53
- BDTX 11.11
About IHD Voya Emerging Markets High Income Dividend Equity Fund
Voya Emerging Markets High Dividend Equity Fund is a diversified closed-end management investment company. Its primary investment objective is to provide total return through a combination of current income, capital gains, and capital appreciation. The company seeks to achieve its investment objectives by investing principally in a portfolio of equity securities, and issuers in emerging market countries. The Fund will also normally seek to secure gains and enhance the stability of returns over a market cycle by writing (selling) call options on selected exchange-traded funds (ETFs) and/or international, regional, or country indices of equity securities, and/or on equity securities.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.